Status:
COMPLETED
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Staphylococcal Infection
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus a...
Eligibility Criteria
Inclusion
- Both Sexes, Aged 20 Years Or Older
- Japanese Participants With Skin And Soft Tissue Infections, Septicemia, or RIE Known Or Suspected To Be Caused By MRSA
- Written Informed Consent
Exclusion
- Participants With Skin and Soft Tissue infections That Can Be Treated By Surgery Alone
- Participants With Pneumonia
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00770341
Start Date
September 1 2008
End Date
February 1 2010
Last Update
March 24 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.